Clinical trials: Systemic Sclerosis, Diffuse
Scleroderma, Mildly Elevated Pulmonary Pressures
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective…
- Trial name
- SEPVADIS (NCT04797286)
- Testing
- Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Diffuse Cutaneous Systemic Sclerosis
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ…
- Trial name
- FREEDOM-3 (NCT05098145)
- Testing
- FCR001
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Scleroderma, Hand Rheumatism
Validity and Reliability of the Turkish Version of HAnDE
The aim of the present study was to translate and cross-culturally adapt The Hand Scleroderma Experienced Experience (HAnDE) Scale into the Turkish language and investigate its reliability and validity in Turkish-speaking…
- Trial name
- NCT06536595
- Testing
- Scales
- Where
- Turkey (Türkiye)
- Volunteers
- 77 people
- Sponsor
- Gazi University
Systemic Sclerosis
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either…
- Trial name
- NCT03844061
- Testing
- Belimumab, Rituximab, MMF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hospital for Special Surgery, New York
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.
- Trial name
- NCT04138485
- Testing
- IgPro10
- Where
- 77 sites in United States, Argentina and 11 more
- Sponsor
- CSL Behring
Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma)
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
The Patient Self-Assessment of Skin Thickness in Upper Limb (PASTUL) questionnaire was developed to enable patients to assess skin thickness in systemic sclerosis (SSc) physically and has been validated for reliability and…
- Conditions
- Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma), Scleroderma (Limited and Diffuse), Patient Perspective
- Trial name
- NCT07182968
- Testing
- Questionnaire study
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hacettepe University
Scleroderma, Systemic
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
GSK2330811 is a humanized monoclonal antibody which is in development for systemic sclerosis (SSc), a rare autoimmune disease with high morbidity and mortality.
- Trial name
- NCT03041025
- Testing
- GSK2330811
- Where
- 14 sites in United States, Canada and 2 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma
Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls
Scleroderma is an autoimmune disease of unknown origin. Recently, the role of environmental factors, and particularly toxic drug exposure, in the genesis of scleroderma has been suggested.
- Trial name
- NCT00213525
- Testing
- Questionnary for environmental factors research
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Systemic Sclerosis (SSc), Scleroderma
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label…
- Trial name
- NCT06843239
- Testing
- Tibulizumab
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 80 people
- Sponsor
- Zura Bio Inc
Systemic Scleroderma
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
Systemic sclerosis (SSc) is a connective-tissue disease characterized by excessive collagen deposition, vascular hyper-reactivity and obliterative microvascular phenomena leading to disability, handicap, and worsening of quality…
- Trial name
- SCLEREDUC (NCT00318188)
- Testing
- standardized reeducation and readaptation program
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Scleroderma
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
Assessment of pulmonary fibrosis is currently based on high-resolution CT (HRCT) and pulmonary function tests (PFT) such as forced vital capacity, (FVC) and carbon monoxide diffusion (DLCO).
- Trial name
- IRMSCLERO (NCT03207997)
- Testing
- unenhanced MR sequences
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Cutaneous Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis
This is a research study of an investigational product called Mycophenolate mofetil (MMF). The study is designed to establish the safety and potential benefit of MMF.
- Trial name
- NCT00433186
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Boston University
Systemic Sclerosis
Open-Label Study of Oral Treprostinil in Digital Ulcers
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects…
- Trial name
- DISTOL-EXT (NCT00848107)
- Testing
- treprostinil diethanolamine
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- United Therapeutics
Scleroderma, Systemic Sclerosis
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States…
- Trial name
- SPIN-SELF (NCT04246528)
- Testing
- SPIN-SELF Program
- Where
- Canada
- Volunteers
- 169 people
- Sponsor
- Lady Davis Institute
Rheumatoid Arthritis, Psoriatic Arthritis
Mindfulness Based Stress Reduction in Rheumatic Diseases
This study will assess the mental health and clinical benefits of Mindfulness Based Stress Reduction (MBSR) in patients with rheumatic disease who have anxiety or depression.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Trial name
- MBSR (NCT03411057)
- Testing
- Mindfulness Based Stress Reduction (MBSR), Control
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Interstitial Lung Disease, Scleroderma
Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease
Interstitial lung disease (ILD) is a diverse group of parenchymal lung disorders characterized by restrictive lung function and impaired alveolar diffusion capacity, leading to dyspnea on exertion, reduced exercise endurance, and…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03560154
- Testing
- Whole Body Vibration Training
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul University
Systemic Sclerosis, Scleroderma
Cardiac Safe Transplants for Systemic Sclerosis
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
- Trial name
- CAST (NCT03593902)
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital